【摘要】：強心苷類藥物的主要藥理機制是抑制心肌細胞膜Na~+-K~+-ATP酶,干擾膜內外相應離子濃度,影響細胞生理功能,致Na~+-Ca~(2+)代償性交換增多,使心肌收縮性增強并表現(xiàn)相應臨床效應。但膜電位的減低使心肌細胞興奮性增高及傳導性下降,為心肌電紊亂提供了可能,也為其臨床應用帶來諸多爭議。特別是當電解質紊亂和心律失常時,對該藥的選擇和使用存在較多疑點,而對該類藥物藥理機制和心肌電生理的正確認識和理解是臨床安全合理用藥的保證。
[Abstract]:The main pharmacological mechanism of cardioside drugs is to inhibit Na~ K- ATP enzyme of myocardial cell membrane, interfere with the corresponding ion concentration inside and outside the membrane, affect the physiological function of cells, and increase the compensatory exchange of Na~ Ca~ (2). The myocardial contractility was enhanced and the corresponding clinical effect was demonstrated. However, the decrease of membrane potential leads to the increase of excitability and the decrease of conduction of myocardial cells, which provides the possibility of myocardial electrical disturbance and brings many controversies to its clinical application. Especially when the electrolyte is in disorder and arrhythmia, there are many doubts about the choice and use of the drug, and the correct understanding and understanding of the pharmacological mechanism and myocardial electrophysiology is the guarantee of safe and reasonable drug use in clinic.
【作者單位】： 陜西省咸陽市第一人民醫(yī)院;
【分類號】：R972

【相似文獻】

相關期刊論文 前2條

1 陳少萍;;強心苷的抗腫瘤治療研究進展[J];藥學服務與研究;2009年06期

2 ;[J];;年期

相關博士學位論文 前1條

1 尹京湘;低濃度強心苷對Na～+/K～+泵電流的興奮作用及強心作用機制[D];河北醫(yī)科大學;2003年

，

本文編號：2320684